Follow-Up Study for Exubera

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines. All subjects diagnosed with lung cancer had a history of smoking and the number of lung cancer cases observed fell within the expected range based on population-based data. There is currently not enough information to determine if any of the observed lung cancer cases were related to Exubera use, therefore, the study is being conducted to further investigate whether Exubera use makes the appearance of lung cancer more likely.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Previously participated in an eligible Exubera clinical trial

• Willing to provide study doctor with at least one alternate contact person

Exclusion Criteria:

• Participated in an investigational study of an unapproved drug since completing the Exubera trial

• Ever used an other (non-Exubera) inhaled insulin